Literature DB >> 23707854

Allogeneic transplantation, Fas signaling, and dysregulation of hepcidin.

Xiang Li1, Feng Xu, Ekapun Karoopongse, A Mario Marcondes, Kayoung Lee, Kris V Kowdley, Carol H Miao, Grant D Trobridge, Jean S Campbell, H Joachim Deeg.   

Abstract

Hepatic iron overload is common in patients undergoing hematopoietic cell transplantation. We showed previously in a murine model that transplantation of allogeneic T cells induced iron deposition and down-regulation of hepcidin (Hamp) in hepatocytes. We hypothesized that hepatic injury was related to disrupted iron homeostasis triggered by the interaction of Fas-ligand, expressed on activated T cells, with Fas on hepatocytes. In the current study, we determined the effects of modified expression of the Flice inhibitory protein (FLIP long [FLIPL]), which interferes with Fas signaling, on the impact of Fas-initiated signals on the expression of IL-6 and Stat3 and their downstream target, Hamp. To exclude a possible contribution by other pathways, we used agonistic anti-Fas antibodies (rather than allogeneic T cells) to trigger Fas signaling. Inhibition of FLIPL by RNA interference resulted, as expected, not only in enhanced hepatocyte apoptosis in response to Fas signals, but also in decreased levels of IL-6, Stat3, and Hamp. In contrast, overexpression of FLIPL protected hepatocytes against agonistic anti-Fas antibody-mediated apoptosis and increased the levels of IL-6 and Stat3, thereby maintaining the expression of Hamp in an NF-κB-dependent fashion. In vivo overexpression of FLIPL in the liver via hydrodynamic transfection, similarly, interfered with Fas-initiated apoptosis and prevented down-regulation of IL-6, Stat3, and Hamp. These data indicate that Fas-dependent signals alter the regulation of iron homeostasis and suggest that signals initiated by Fas may contribute to peritransplantation iron accumulation.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; FLIP Long; Hepcidin; Iron

Mesh:

Substances:

Year:  2013        PMID: 23707854      PMCID: PMC3720784          DOI: 10.1016/j.bbmt.2013.05.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  48 in total

1.  Hepatoprotection via the IL-6/Stat3 pathway.

Authors:  Rebecca Taub
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

2.  The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex.

Authors:  Olivier Micheau; Margot Thome; Pascal Schneider; Nils Holler; Jürg Tschopp; Donald W Nicholson; Christophe Briand; Markus G Grütter
Journal:  J Biol Chem       Date:  2002-09-04       Impact factor: 5.157

Review 3.  Regulation of lymphocyte proliferation and death by FLIP.

Authors:  M Thome; J Tschopp
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

4.  Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway.

Authors:  S Faouzi; B E Burckhardt; J C Hanson; C B Campe; L W Schrum; R A Rippe; J J Maher
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

5.  Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

Authors:  Constantine S Mitsiades; Nicholas Mitsiades; Vassiliki Poulaki; Robert Schlossman; Masaharu Akiyama; Dharminder Chauhan; Teru Hideshima; Steven P Treon; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Oncogene       Date:  2002-08-22       Impact factor: 9.867

6.  Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma.

Authors:  Hiroshi Okano; Katsuya Shiraki; Hidekazu Inoue; Tomoyuki Kawakita; Takenari Yamanaka; Masatoshi Deguchi; Kazushi Sugimoto; Takahisa Sakai; Shigeru Ohmori; Katsuhiko Fujikawa; Kazumoto Murata; Takeshi Nakano
Journal:  Lab Invest       Date:  2003-07       Impact factor: 5.662

7.  High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors.

Authors:  Carol H Miao; Xin Ye; Arthur R Thompson
Journal:  Hum Gene Ther       Date:  2003-09-20       Impact factor: 5.695

8.  Phosphatidylinositide 3-kinase priming couples c-FLIP to T cell activation.

Authors:  Li-Wen Fang; Tzong-Shyuang Tai; Wan-Ni Yu; Fang Liao; Ming-Zong Lai
Journal:  J Biol Chem       Date:  2003-10-24       Impact factor: 5.157

9.  Prevention of Fas-mediated hepatic failure by transferrin.

Authors:  Vladimir A Lesnikov; Marina P Lesnikova; Howard M Shulman; Heather-Marie Wilson; David M Hockenbery; Markus Kocher; Walter Pierpaoli; H Joachim Deeg
Journal:  Lab Invest       Date:  2004-03       Impact factor: 5.662

10.  N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway.

Authors:  Takao Kataoka; Jürg Tschopp
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

View more
  4 in total

1.  Disruption of Iron Regulation after Radiation and Donor Cell Infusion.

Authors:  Ekapun Karoopongse; A Mario Marcondes; Cecilia Yeung; Zaneta Holman; Kris V Kowdley; Jean S Campbell; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-07       Impact factor: 5.742

2.  Apoptosis induced by Fas signaling does not alter hepatic hepcidin expression.

Authors:  Sizhao Lu; Emily Zmijewski; John Gollan; Duygu Dee Harrison-Findik
Journal:  World J Biol Chem       Date:  2014-08-26

3.  Green tea activity and iron overload induced molecular fibrogenesis of rat liver.

Authors:  Gadah I Al-Basher
Journal:  Saudi J Biol Sci       Date:  2017-08-18       Impact factor: 4.219

4.  Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.

Authors:  Michelle Pirotte; Marianne Fillet; Laurence Seidel; Aurélie Jaspers; Fréderic Baron; Yves Beguin
Journal:  Am J Hematol       Date:  2021-08-24       Impact factor: 13.265

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.